Artificial Insemination Market Size, Share, Growth & Industry Analysis, By Type (Intrauterine, Intracervical, Intravaginal, Intratubal), Source (Husband, Donor), End-Use (Hospitals, Fertility Clinics), and Regional Analysis, 2024-2031

Global Artificial Insemination Market Size

The global artificial insemination market size was valued at USD 2280 million in 2023 and is projected to grow from USD 2445.1 million in 2024 to USD 4282.9 million by 2031, exhibiting a CAGR of 8.34% during the forecast period.

The expansion of the global market is attributed to advancements in hormone treatment regimens, the rising prevalence of infertility among male and female populations, the increasing success rates of artificial insemination procedures, and the growing population of same-sex couples seeking family planning options.

In the scope of work, the report includes products offered by companies such as Vitrolife, A CooperSurgical Fertility Company, Cook, Genea BIOMEDX, Hamilton Thorne, Medtronic, PFCLA, Mayo Clinic, Virtus Health, City Fertility, among and others.

The global artificial insemination market is experiencing rapid growth, driven by the integration of advanced technologies and AI-powered tools. Fertility clinics and hospitals are actively engaged in refining existing techniques and developing innovative, minimally invasive procedures designed to enhance patient comfort and minimize potential complications.

Moreover, ongoing research and development efforts are exploring the feasibility and safety of home-based artificial insemination procedures, with the objective of increasing accessibility and affordability for patients seeking these critical reproductive services.

• In January 2024, PherDal Fertility Science, Inc. received approval from the Food and Drug Administration (FDA) for its innovative at-home intrauterine insemination kit. This comprehensive kit includes three single-use insemination syringes and cups for patient use.

Artificial insemination is a fertility treatment that involves introducing sperm into the uterus to achieve pregnancy. Depending upon the patient's specific needs and medical conditions, physicians may recommend various methods, including intrauterine, intracervical, intravaginal, and intratubal insemination.

These procedures are typically performed by qualified medical professionals within the controlled environment of hospitals or specialized fertility clinics.

Analyst’s Review

The rising infertility rates among both men and women have  significantly boosted the demand for artificial insemination procedures in countries including the US, India, China, the UK, Brazil, and others. Increasing stress at work, unhealthy dietary habits, consumption of alcohol and other toxins are primary factors contributing to infertility.

To address the growing demand, fertility clinics and hospitals are employing advanced technologies and AI-powered tools to reduce discomfort and increase success rates. Additionally, they are partnering with insurance firms to make artificial insemination procedures, including IUI and ICI, more affordable and accessible to patients in need.

• For instance, in August 2024, Aetna, a CVS Health company, made a significant advancement in healthcare coverage by becoming the first major insurer to expand coverage and simplify access to fertility services. The company now includes Intrauterine Insemination (IUI) as a covered medical benefit for eligible plans, demonstrating the company's commitment to enhancing women's health and supporting the well-being of the LGBTQ+ community and unpartnered individuals.

Furthermore, ongoing research and development efforts are focused on the creation of over-the-counter kits that replicate the process of intrauterine insemination (IUI). The development of these kits necessitates a meticulous approach, ensuring compliance with regulatory requirements and ethical standards to protect patient safety and well-being.

• In December 2023, the FDA granted approval to Mosie Baby's innovative at-home syringe insemination kit, marking a significant milestone in the field of assisted reproductive technologies. This approval allows couples to perform intravaginal insemination procedures within the comfort and privacy of their own homes.

Artificial Insemination Market Growth Factors

The growing number of same-sex couples and single women seeking to start families is significantly contributing to the growth of the market. This is leading to increased demand for assisted reproductive technologies (ARTS) such as intracervical insemination (ICI) and intrauterine insemination (IUI).

The increasing social acceptance and reduced stigma associated with diverse family structures have further stimulated the growth of the artificial insemination market.

• A study conducted by the National Institutes of Health demonstrated that pregnancy outcomes for lesbian women undergoing intrauterine insemination (IUI) for procreative management are comparable to those of heterosexual women. However, the study noted that heterosexual women generally undergo a higher number of IUI cycles, likely attributable to the higher prevalence of male factor infertility within this population.

Despite the expansion of the market, several significant challenges persist, including ethical concerns regarding donor anonymity, substantial treatment costs, and other logistical considerations. To mitigate these challenges, numerous clinics have implemented more rigorous screening procedures for sperm donors, including comprehensive genetic testing and in-depth psychological evaluations.

Furthermore, many clinics offer flexible payment plans and financial assistance programs to enhance the accessibility and affordability of artificial insemination procedures for patients.

Artificial Insemination Industry Trends

A growing segment of working population is delaying parenthood, increasing the likelihood of age-related fertility issues in both men and women. Furthermore, unhealthy lifestyles and substance consumption have exacerbted infertility issues.

• A study published by the World Health Organization in April 2023 revealed that approximately 17.5% of the adult population worldwide experiences infertility. Despite the growing prevalence of infertility, the report emphasizes the critical need to expand access to fertility care and prioritize investing in health research and policy initiatives.

Technological advancements have played a pivotal role in fueling the growth of the artificial insemination market, leading to improved success rates and expanded access to treatment.

Significant investments in research have led to the development of techniques such as density gradient centrifugation and magnetic-activated cell sorting (MACS), which are employed to separate high-quality sperm from the sample, thereby enhancing the probability of fertilization.

Moreover, companies are leveraging the power of computer software and AI tools to analyze sperm motility, morphology, and concentration, providing objective and accurate assessments of sperm quality.

• In December 2024, the Indian Council of Medical Research, in collaboration with researchers from Amity University, developed an AI tool to predict sperm retrieval rates and success rates of ART in men with Y chromosome microdeletion. This AI-based tool assesses fertilization, clinical pregnancy, and live birth rates based on Y chromosome types.

Segmentation Analysis

The global market has been segmented based on type, source, end-use, and geography.

By Type

Based on the type, the market has been categorized broadly into intrauterine, intracervical, intravaginal, and intratubal insemination. The intrauterine insemination (IUI) segment dominated the artificial insemination market, with a revenue of USD 1040.8 million in 2023.

Intrauterine insemination (IUI) is a widely preferred artificial insemination techniques due to its shorter procedure time, and minimal discomfort, and cost-effectiveness.

By placing sperm directly into the uterine cavity, IUI increases the likelihood of fertilization by increasing the number of healthy sperm reaching the fallopian tubes during the fertile period. Compared to in-vitro fertilization (IVF), IUI is less invasive and more economical, making it a popular choice among couples.   

By Source

Based on the source, the artificial insemination market has been categorized into artificial insemination with husband sperm (AIH) and artificial insemination with donor sperm (AID). The artificial insemination with donor sperm (AID) segment is projected to reach a valuation of USD 1070.6 million in 2024, demonstrating a rapid CAGR of 8.96% through the forecast period.

The rising demand for donor sperm is attributed to expanding social acceptance and change in societal norms regarding family structure. The growing utilization of assisted reproductive technologies (ARTs) by single women and same-sex couples has supported this increased demand.

Furthermore, advancements in sperm banking technologies, including advanced cryopreservation techniques, have enhanced the availability and quality of donor sperm. The emergence of online sperm banks and donor registries has further facilitated access to donor sperm for individuals and couples seeking these services.

By End-Use

Based on the end-use, the market has been segmented into hospitals and fertility clinics.The fertility clinics segment held the largest revenue share of 57.88% in 2023, generating a revenue of USD 1319.7 million. Fertility clinics are specifically designed to provide comprehensive care for individuals and couples facing infertility, including artificial insemination (AI) services.

These specialized clinics further offer advanced solutions such as in vitro fertilization (IVF), egg donation, surrogacy, and genetic counseling. Fertility clinics are staffed by highly qualified professionals, including reproductive endocrinologists, embryologists, and nurses, with extensive expertise in fertility procedures.

Moreover, fertility clinics often have access to cutting-edge technologies and advanced equipment for sperm preparation, embryo selection, and other critical aspects of AI treatment, which can significantly enhance the success rates of these procedures.

Artificial Insemination Market Regional Analysis

Based on the region, the global market has been classified into North America, Europe, Asia Pacific, MEA, and Latin America.

The North America artificial insemination market accounted for a substantial share of 35.43% and was valued at USD 830.6 million in 2023. North America boasts a robust healthcare infrastructure with by a high concentration of specialized fertility clinics and experienced professionals.

The region's high per capita healthcare expenditures facilitates greater access to advanced fertility treatments that integrate AI-powered tools. Furthermore, widespread awareness and acceptance of assisted reproductive technologies (ARTs) reduce social stigma, further enhancing accessibility to these treatments

The Asia-Pacific generated a revenue of USD 1105.7 million in 2023. Government-led public awareness campaigns are pivotal in educating the public about infertility, available treatment options, and the importance of professional medical guidance. These initiatives also provide emotional support and foster connections among individuals facing infertility challenges.

These campaigns have effectively increased public awareness and encouraged couples to consider artificial insemination as a viable option for family planning. 

Competitive Landscape

The global artificial insemination market report will provide valuable insights with a specialized emphasis on the fragmented nature of the industry. Prominent players are focusing on several key business strategies, such as partnerships, mergers and acquisitions, product innovations, and joint ventures, to expand their product portfolio and increase their market shares across different regions.

Companies are implementing impactful strategic initiatives, such as expansion of services, investments in research and development (R&D), establishment of new service delivery centers, and optimization of their service delivery processes, which are likely to create new opportunities for market growth.

List of Key Companies in Artificial Insemination Market

• Vitrolife
• A CooperSurgical Fertility Company 
• Cook
• Genea BIOMEDX
• Hamilton Thorne
• Medtronic
• PFCLA
• Mayo Clinic
• Virtus Health
• City Fertility

Key Industry Developments

• October 2024 (Partnership):  Hamilton Thorne Inc., entered into a partnership with Alife Health, a company specializing in the development of AI-powered tools for in-vitro fertilization (IVF). The collaboration aims to leverage Alife Health's Clinical Decision Support (CDS) algorithm to optimize embryo selection for its clients.
• October 2024 (Product Launch): Cook Medical, a prominent family-owned medical device company, launched NestVT, an innovative vitrification device for IVF clinics. This innovative device is designed to ensure the secure handling of embryos and oocytes throughout the vitrification, cryo-storage, and relocation processes.
• March 2024 (Partnership): City Fertility Clinic partnered with Menopause Alliance Australia to organize the inaugural Women's Life Cycle Summit in Australia, held in March 2024. This significant event gathered leading women's health specialists to address critical issues such as infertility and early menopause.

The global artificial insemination market has been segmented as:

By Type

• Intrauterine Insemination
• Intracervical Insemination
• Intravaginal Insemination
• Intratubal Insemination

By Source

• AIH-Husband
• AID-Donor

By End-Use

• Hospitals
• Fertility Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • UK
  • Spain
  • Germany
  • Italy
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Middle East & Africa
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America